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Abstract Osteoporosis is a recognised complication of
axial spondyloarthritis (axSpA) and is thought to be due to
functional impairment and the osteoclast-activating effects
of proinflammatory cytokines. The development of
autoantibodies to OPG (OPG-Ab) has been associated with
severe osteoporosis and increased bone resorption in
rheumatoid arthritis. In this study, we screened for the
presence of OPG-Ab in axSpA and reviewed their clinical
significance. We studied 134 patients, recruited from two
centres in the United Kingdom. Their mean age was
47.5 years and 75% were male. Concentrations of OPG-Ab
were related to bone mineral density (BMD) and fracture
history using linear and logistic regression models adjust-
ing for age, gender, disease duration and activity, body
mass index and bisphosphonate use. We detected OPG-Ab
in 11/134 patients (8.2%). Femoral neck and total hip BMD
were significantly reduced in OPG-Ab positive patients
(0.827 vs. 0.967 g/cm2, p = 0.008 and 0.868 vs. 1.028 g/
cm2, p = 0.002, respectively). Regression analysis showed
that the presence of OPG-Ab was independently associated
with total hip osteopenia (ORadj 24.2; 95% CI 2.57, 228)
and history of fractures (ORadj 10.5; 95% CI 2.07, 53.3).
OPG-Ab concentration was associated with total hip BMD
in g/cm2 (ß = -1.15; 95% CI -0.25, -0.04). There were
no associations between OPG-Ab concentration and bone
turnover markers, but free sRANKL concentrations were
lower in OPG-Ab-positive patients (median 0.04 vs.
0.11 pmol/L, p = 0.050). We conclude that OPG-Ab are
associated with hip BMD and fractures in axSpA sug-
gesting that they may contribute to the pathogenesis of
bone loss in some patients with this condition.
Keywords Ankylosing spondylitis  Axial
spondyloarthritis  Osteoporosis  Bone mineral density 
Osteoprotegerin
Introduction
Axial spondyloarthropathy (axSpA) is characterised by
inflammation of the sacroiliac joints and entheses. Disease
progression involves not only new bone formation at sites
of inflammation but also, paradoxically, an increased risk
of osteoporosis and vertebral fractures [1–3]. Osteoporosis
is present in up to 25% of patients [4] and vertebral frac-
tures have been reported in up to 30% of patients [5, 6].
Both can occur in early disease [7, 8]. In contrast to the
general population, axSpA-associated osteoporosis is more
prevalent in men and occurs at younger ages [8], which
limits the value of conventional fracture risk assessment
tools such as FRAX [9].
AxSpA shares many factors in common with other
inflammatory arthropathies that are associated with accel-
erated bone loss, including impaired physical mobility [8]
and increased production of cytokines such as TNF and
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IL17 which stimulate osteoclastic bone resorption [10].
Although the patterns of bone involvement differ in
rheumatoid arthritis (RA) and axSpA, the final common
pathway of bone loss in both cases is increased osteoclastic
bone resorption which is critically dependent on the stim-
ulatory effects of RANKL, counterbalanced by the inhi-
bitory effects of OPG [11]. However, axSpA also differs in
that it has younger age of onset, male predominance and
lower systemic inflammatory burden. Other novel factors
may therefore be associated with the development of pre-
mature osteoporosis and fractures in the axSpA population.
Autoantibodies to osteoprotegerin (OPG-Ab) were pre-
viously identified as a cause of high turnover osteoporosis
in a patient with coeliac and autoimmune thyroid disease
[12]. OPG-Abs have also been detected in patients with
RA, where they were associated with increased bone
resorption [13] and in coeliac disease where they were
associated with reduced BMD [14]. The aim of this study
was to determine if OPG-Abs were present in axSpA and to
explore whether they were associated with BMD or history
of fractures.
Methods
We enrolled consecutive axSpA patients who presented to
specialist rheumatology clinics at Aintree University
Hospital in Liverpool and the Western General Hospital in
Edinburgh, between July 2011 and February 2015. Patients
were included in the study if they met the modified New
York criteria for ankylosing spondylitis [15] and/or the
ASAS criteria for axSpA [16].
We recorded demographic information, disease charac-
teristics (age at diagnosis, HLA-B27 status if available,
extra-axial involvement), and current medication [NSAIDs,
DMARDs, calcium/vitamin D, bisphosphonates and TNF
inhibitors (TNFi)], ever-smoking, current glucocorticoid
use and body mass index (BMI). We enquired about a
history of clinical fractures and fracture site (vertebral or
non-vertebral). Clinical notes and radiographs were
reviewed to verify self-reported fractures. Disease duration
was defined as the number of years since first diagnosis.
Disease activity was assessed using the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), spinal pain
visual analogue scale (spVAS) and Bath AS Functional
Index (BASFI). Blood samples were obtained for erythro-
cyte sedimentation rate (ESR) and C-reactive protein
(CRP) using the local hospital laboratories. Serum samples
were also prepared at the time of enrolment and stored at
-80 C until use for measurement of specialised markers
of bone turnover and OPG-Ab as described below.
Bone mineral density (BMD) was assessed using
anteroposterior DXA of the lumbar spine (L1–L4), femoral
neck and total hip using Lunar iDXA (GE Healthcare) at
Liverpool and Hologic QDR4500 at Edinburgh. Hologic
BMD values in g/cm2 were converted to Lunar equivalents
as manufacturer’s recommendations [17, 18]. Osteopenia
and osteoporosis were defined as T-scores\-1 and B-2.5,
respectively [19].
Measurement of OPG-Ab was performed at the Centre
for Genomic and Experimental Medicine by an indirect
ELISA developed in-house as described previously [14]. A
standard curve comprising serial dilutions of serum from
the index case was run on each plate with an arbitrary value
of 100 units assigned to neat serum. The concentrations of
OPG-Ab were estimated from this standard curve. Each
sample was run in triplicate and repeated at least once on a
different day. One result of each triplicate was discarded as
an outlier if it was more than three standard deviations
outside the mean of two most concordant values, except
where the two most concordant values were identical. The
mean of the remaining values was used for analysis. Inter-
and intra-assay coefficients of variation (CV) for positive
OPG-Ab ELISA titre were 16.6 and 17.3%, respectively. A
previous study of 100 healthy controls [mean age 57.8
(SD ± 12)] with normal BMD demonstrated a mean titre
of 3.46 (SD ± 3.64) and was used to define the limit for
OPG-Ab positivity [14]. Positive OPG-Ab was defined as
titres three standard deviations above the mean [20], which
equates to C14.3 units.
Measurements of OPG, free soluble RANKL
(sRANKL), the N-terminal pro-peptide of type I collagen
(PINP) and the C-terminal type 1 crosslinked telopeptide
(CTX) were performed at the University of East Anglia
bioanalytical facility. Measurements of CTX (ng/ml) and
PINP (ng/ml) were performed on COBAS 6000 (Roche
Diagnostics) with an inter-assay CV of 3.9 and 4.0%,
respectively. Concentrations of OPG (pmol/L) and free
sRANKL (pmol/L) were measured using ELISA kits
(Biomedica, Austria) following manufacturer’s instruc-
tions. Performance of these kits (on duplicated samples)
was intra-assay CV 3.1% for OPG and 3.8% for sRANKL.
Inter-assay CV were 6.6% for OPG (n = 4) and 4.1% for
sRANKL (n = 3) across the standard curve concentrations
for the assay. Reference ranges for sRANKL, CTX and
PINP were obtained from the manufacturer literature, and
for OPG from the population study [21]: OPG (male
0.124–10.690 pmol/L; female 0–11.475 pmol/L),
sRANKL (male 0.022–0.381 pmol/L; female
0.020–0.329 pmol/L), CTX (male 0.158–0.442 ng/ml;
female 0.092–0.436 ng/ml) and PINP (male 20–76 ng/ml;
female 15–59 ng/ml).
Statistical analyses were performed using Stata13. Data
from both study sites were combined for analyses. Com-
parative analysis was performed using Mann–Whitney
U test for non-normally distributed variables, Student’s
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t test for normally distributed variables and Fisher’s exact
test for categorical variables. Associations between OPG-
Ab concentration and OPG, free sRANKL, CTX and PINP
were assessed using Spearman’s rank correlation in the
total cohort and separately in patients who were not
receiving bisphosphonates. Association between positive
OPG-Ab and disease characteristics was assessed with
univariate logistic regression. Correlation between BMD
(g/cm2) and OPG-Ab concentration was demonstrated
using scatter graphs.
In the first instance, regression models were used to
assess associations between measures of bone density and
OPG-Ab positivity as the independent variable. Linear
models were used for BMD (g/cm2), T- and Z-scores as
dependent variables, adjusted for age (not included in Z-
score model), gender, disease duration, bisphosphonate
use, BASDAI and BMI. Logistic models were used for
osteopenia, osteoporosis and fractures as dependent vari-
ables, using the same covariates. No imputation was per-
formed for missing data; therefore, multivariable models
were limited to a subgroup with complete data for all
covariates. In addition to analyses of OPG-Ab positivity,
the same linear and logistic models were generated using
OPG-Ab concentration as the independent variable.
Residuals of linear models were tested against a normal
distribution using kernel density plots and skewness–kur-
tosis test. Finally, backward stepwise regression analyses
were performed to identify independent explanatory vari-
ables for total hip, femoral neck and spine g/cm2 each as
the dependent variable, using p[ 0.1 as criteria for
removal from the full model. Significant association was
defined as p\ 0.05.
Results
The axSpA cohort comprised 134 patients: 53 from Edin-
burgh and 81 from Liverpool. There were no significant
differences in patient or disease characteristics between the
two study sites (data not shown). The median OPG-Ab titre
was 2.8 (range 0.2, 36; interquartile range [IQR] 1.4, 4.3).
A positive OPG-Ab result was detected in 11 patients
(8.2%). There was no difference in proportion of positive
OPG-Ab between study sites (p = 0.526). Demographics
and disease characteristics of patients positive and negative
for OPG-Ab are shown in Table 1. The cohort was pre-
dominantly male (75%) with a mean age of 47.5 years
(SD ± 15) and medium disease duration of 6.4 years [IQR
1.9, 17.8]. Patients positive for OPG-Ab were older and
had longer disease duration. They were also lower in
height, although BMI was similar between the groups.
The BASDAI scores were generally high (median 5.4)
with no significant difference between the OPG-Ab
positive and negative groups. Peripheral joint involvement
was reported in 35% of patients and 11% had associated
inflammatory bowel disease. A third of patients were
treated with TNFi and 64% were on NSAIDs at the time of
recruitment. A greater proportion of patients positive for
OPG-Ab were currently using TNFi (p = 0.043) and bis-
phosphonates (p = 0.006).
Bone density measurements were available in 120
patients, measured within a median of 0.2 months [IQR
-9.6, 2.9] from the study visit. Existing DXA results were
available for 50% of patients and a further 50% had scans
organised at the time of the study assessment. Most scans
(79%) were performed within 12 months of the study
assessment. Spinal BMD was not measured for one patient
due to significant aortic calcification. Hip BMD was not
measured in two patients who had bilateral hip replace-
ments. Differences between patients positive and negative
for OPG-Ab are shown in Table 1. No significant differ-
ences in BMD were observed at the spine. Total hip and
femoral neck BMD (g/cm2) and T-scores were all signifi-
cantly lower in OPG-Ab positive patients. The same was
true for Z-score (data not shown). Osteopenia of the total
hip and femoral neck was significantly more common in
OPG-Ab-positive patients (82 vs. 28%, p\ 0.001 and 82
vs. 35%, p = 0.007, respectively). The same was true for
osteoporosis of total hip and femoral neck (18 vs. 1%,
p = 0.023 and 27 vs. 6%, p = 0.039, respectively).
A history of fracture was reported by 35 (26%) patients.
Three patients (2%) had multiple vertebral fractures and 32
(24%) had non-vertebral fractures. OPG-Ab positive
patients had a higher proportion of self-reported fractures
(p = 0.007). Radiographs and/or clinical notes were
available to confirm 17 of the self-reported fractures.
In the whole study cohort, the median level of OPG was
4.2 pmol/L [IQR 3.4, 4.9], sRANKL 0.11 pmol/L [IQR
0.04, 0.18], CTX 0.22 ng/mL [IQR 0.16, 0.32] and PINP
42 ng/mL [IQR 30, 55]. For OPG, 99% of the cohort were
within the reference range, 77% for sRANKL, 71% for
CTX and 88% for PINP. Serum concentrations of OPG,
sRANKL, PINP and CTX in relation to OPG-Ab status are
shown in Fig. 1. Concentrations of free sRANKL were
lower in OPG-Ab positive group (p = 0.050) but there was
no significant difference between the groups for concen-
trations of OPG, NTX or PINP. An inverse correlation was
observed between OPG-Ab concentration and total hip and
femoral neck BMD but not for spine BMD (Fig. 2). Similar
correlations were observed for Z-scores (not shown).
Univariate logistic regression demonstrated significant
associations between OPG-Ab positivity and disease
duration (OR 1.05; 95% CI 1.01, 1.10) and age (OR 1.04;
95% CI 1.00, 1.09). Multi-adjusted regression models
showed significant associations between positive OPG-Ab
status and total hip BMD (g/cm2), T- and Z-scores
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Table 1 Patient and disease
characteristics by OPG-Ab
status
Positive n = 11 Negative n = 123 p-value
Demographics
Age (years) 56.1 ± 15.5 46.2 ± 14.7 0.036
Males 8 (73%) 92 (75%) 1.000
HLA-B27 (n = 59) 3 (60%) 39 (72%) 0.620
Age diagnosed 43.3 ± 15.1 40.9 ± 14.5 0.610
Median years disease duration 22.3 [0.8, 33.1] 5.6 [1.9, 16.3] 0.067
Ever smokers 5 (45%) 40 (33%) 0.510
Height (cm) (n = 130) 164 ± 7.5 171 ± 9.6 0.018
Weight (kg) (n = 132) 78.6 ± 14.5 81.4 ± 17.3 0.609
BMI (kg/m2) (n = 130) 29.3 ± 5.9 27.8 ± 5.8 0.391
Disease activity
Median BASDAI (n = 132) 3.9 [2, 5.7] 5.5 [3.2, 7.7] 0.137
Median spVAS (n = 126) 5 [2, 8] 6 [2.9, 8] 0.741
Median BASFI (n = 106) 4 [3.4, 8.5] 5.3 [3.4, 7.4] 0.869
Median ESR (mm/h) (n = 111) 14 [5, 27] 8 [5, 17] 0.420
Median CRP (mg/L) (n = 109) 1 [1, 6] 4 [1, 9] 0.230
Extra-axial involvement
Peripheral joint involvement 4 (36%) 42 (34%) 1.000
Psoriasis 2 (18%) 18 (15%) 0.671
Uveitis 2 (18%) 44 (36%) 0.329
Inflammatory bowel disease 1 (9%) 14 (11%) 1.000
Medication
TNF inhibitor 7 (64%) 38 (31%) 0.043
Synthetic DMARD 0 15 (12%) 0.256
NSAIDs 6 (55%) 77 (65%) 0.520
Glucocorticoid 1 (9%) 2 (2%) 0.228
Bisphosphonates 4 (36%) 7 (6%) 0.006
Calcium and vitamin D 7 (64%) 57 (46%) 0.271
Lumbar spinea
g/cm2 1.226 ± 0.189 1.231 ± 0.235 0.947
T-score 0.2 ± 1.5 0.1 ± 2.0 0.963
Femoral neckb
g/cm2 0.827 ± 0.131 0.967 ± 0.166 0.008
T-score -1.68 ± 1.04 -0.57 ± 1.22 0.004
Osteopenia 9 (82%) 37 (35%) 0.007
Osteoporosis 3 (27%) 6 (6%) 0.039
Total hipb
g/cm2 0.868 ± 0.142 1.028 ± 0.157 0.002
T-score -1.5 ± 1.0 -0.3 ± 1.1 0.001
Osteopenia 9 (82%) 30 (28%) 0.001
Osteoporosis 2 (18%) 1 (1%) 0.023
History of fractures 7 (64%) 28 (23%) 0.007
Data shown as mean ± standard deviation; median [interquartile range]; number (percentage)
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, spVAS spinal pain visual analogue scale,
BASFI Bath AS Functional Index, BMD bone mineral density, OPG-Ab anti-OPG antibody, n number of
available data)
a Measures of spine BMD were missing for one patient due to significant aortic calcification
b Measures of hip BMD were missing for two patients due to bilateral hip replacements
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(Table 2). Similar trends were observed for femoral neck
BMD but significance was reached only for the association
between femoral neck Z-score and OPG-Ab positivity.
Positive OPG-Ab status was strongly associated with
osteopenia at the total hip (ORadj 24.2; 95% CI 2.57, 228)
and femoral neck (ORadj 21.3; 95% CI 1.96, 231) but not
osteoporosis. In contrast, there was no association between
OPG-Ab and lumbar spine BMD (g/cm2), T- or Z-scores.
OPG-Ab positivity was significantly associated with his-
tory of self-reported fractures (ORadj 10.5; 95% CI 2.07,
53.3). In regression models of OPG-Ab concentration, the
same associations were demonstrated for measures of total
hip BMD, osteopenia and previous fractures (Table 2).
Post hoc analyses including TNFi as additional covariates
in these models did not alter the effect sizes, and model
comparisons using likelihood ratio test were not significant
(data not shown). Residuals from linear models were nor-
mally distributed. Stepwise regression revealed that OPG-
Ab concentration, age, gender and BMI were indepen-
dently and significantly associated with total hip BMD (g/
cm2). In contrast, only age and bisphosphonate use were
associated with femoral neck BMD (g/cm2), while age,
gender and BMI were associated with spinal BMD (g/cm2).
No associations were observed between positive OPG-
Ab status or concentration and markers of disease activity
(data not shown). OPG-Ab concentration was associated
with OPG (q = 0.17, p = 0.046) but not with sRANKL.
There were no associations between OPG-Ab and CTX/
PINP in the total cohort, nor in the subgroup not receiving
bisphosphonates. sRANKL was associated with OPG
(q = -0.38, p\ 0.001) and PINP (q = 0.19, p = 0.032),
and PINP was associated with CTX (q = 0.70, p\ 0.001).
Serum concentrations of OPG, sRANKL, CTX and PINP
were not associated with fractures, hip or spine BMD (data
not shown).
Discussion
This cross-sectional study has demonstrated that 8.2% of
patients with established axSpA were positive for OPG-Ab.
These autoantibodies were independently associated with
reduced hip BMD and a history of self-reported fractures.
Adjusted for confounders, regression models showed that
patients positive for OPG-Ab had lower total hip BMD by
0.15 g/cm2 or 1 unit in T-score than those who were neg-
ative. For each unit increase in OPG-Ab concentration,
total hip T-score was 0.05 unit lower. Participants positive
for OPG-Ab had 24-fold increased likelihood of hip
osteopenia and tenfold increased likelihood of reporting a
prior fracture.
The prevalence of positive OPG-Ab is similar to that
reported in RA (9.3%) and coeliac disease (9.8%) but is
significantly higher than that reported in healthy controls
(1–1.4%) [13, 14]. This was unexpected since axSpA is not
classically associated with the development of
autoantibodies.
Previous studies have demonstrated associations
between OPG-Ab and severe osteoporosis and fractures in
a patient with coeliac disease and hypothyroidism, as well
as increased bone resorption in RA and low BMD in
coeliac disease [12–14]. However, this is the first study to
show that positive OPG-Ab is associated with reduced hip
BMD in axSpA. The lack of association with spine BMD
Fig. 1 Biochemical markers of
bone metabolism and OPG
antibody status
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Fig. 2 Scatter plot of anti-OPG
antibody concentration against
bone mineral density (g/cm2) of
total hip, femoral neck and
lumbar spine. Lines show least
square lines of best fit
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may reflect syndesmophytes increasing anteroposterior
BMD, even though there may be osteoporosis affecting the
trabecular compartment of the vertebrae [1]. Future studies
should utilise lateral DXA scans or quantitative CT to
investigate the vertebral trabecular compartment BMD in
relation to OPG-Ab in axSpA.
Since previous studies have shown that OPG-Abs block
the inhibitory effect of OPG on RANKL-induced NFjB
signalling in vitro, this provides an explanation for the
association between OPG-Ab and bone loss [12, 13]. The
findings reported here suggest that these antibodies may
also contribute to the pathogenesis of systemic bone loss in
some axSpA patients. Nonetheless, we acknowledge that
OPG-Abs are likely to be only one of many contributory
factors to the pathogenesis of bone loss in this complex
disease.
In order to explore the pathophysiological mechanisms
by which OPG-Ab were associated with reduced BMD in
this population, we studied the relation between biochem-
ical markers of bone resorption and bone formation and
OPG-Ab, as well as possible associations between OPG-Ab
and levels of OPG and free sRANKL. We were surprised to
find a positive association between circulating levels of
OPG and OPG-Ab. This has not been observed before [22]
but a possible explanation might be that in some axSpA
cases, local or systemic release of OPG may trigger an
OPG-Ab response. We also found a negative correlation
between OPG-Ab and free sRANKL concentrations. This
is likely to be due to interference of OPG-Ab with the
Biomedica sRANKL assay since this ELISA uses OPG as
the capture antigen. It is therefore likely that OPG-Ab
binds to the capture antigen, and in doing so blocks its
ability to bind to free sRANKL. We found no correlation
between OPG-Ab and CTX or PINP concentrations
although this may have been due to the fact that one-third
of patients with OPG-Ab were on bisphosphonates for the
treatment of their osteoporosis. Further studies in untreated
patients with axSpA would be warranted to determine if
OPG-Ab are associated with increased bone turnover as has
been reported previously [12, 13].
Patients positive for OPG-Ab were older and had longer
disease duration. It is known that autoantibody production
increases with age. However, associations in this study
remained significant after adjusting for both age and dis-
ease duration. An association was found between OPG-Ab
positivity and increasing disease duration, which was also
observed in RA [13]. The reason for this association
remains unexplained but we hypothesise that a cycle of
chronic inflammation, B and T-cell proliferation and
chronically increased RANKL/OPG concentrations may
Table 2 Multivariable linear and logistic regression models demonstrating associations between BMD and fractures and OPG-Ab, adjusted for
age, gender, disease duration, bisphosphonate use, BASDAI and BMI (age was not included for Z-score models)
OPG-Ab positivity OPG-Ab concentration
Effect size 95% confidence
interval
R2/pseudo
R2
Effect size 95% confidence
interval
R2/pseudo
R2
Total hip BMD (g/cm2) b = 20.15 20.25, 20.04 0.26 b = 20.01 20.01, 20.00 0.26
Total hip T-score b = 21.06 21.82, -0.30 0.21 b = 20.05 20.09, 20.02 0.22
Total hip Z-score b = 21.12 21.88, 20.36 0.11 b = 20.05 20.09, 20.02 0.11
Femoral neck BMD (g/cm2) b = -0.09 -0.20, 0.02 0.25 b = -0.00 -0.01, 0.00 0.25
Femoral neck T-score b = -0.72 -1.52, 0.07 0.27 b = -0.03 -0.07, 0.00 0.27
Femoral neck Z-score b = 20.79 21.58, 20.01 0.11 b = -0.03 -0.07, 0.00 0.10
Lumbar spine BMD (g/cm2) b = -0.06 -0.21, 0.08 0.27 b = -0.00 -0.01, 0.00 0.27
Lumbar spine T-score b = -0.47 -1.69, 0.76 0.23 b = -0.02 -0.07, 0.04 0.23
Lumbar spine Z-score b = -0.73 -2.00, 0.55 0.21 b = -0.02 -0.08, 0.04 0.21
Total hip osteopenia (T-score\-1) ORadj 24.2 2.57, 228 0.19 ORadj 1.19 1.07, 1.31 0.21
Total hip osteoporosis (T-score B-2.5) ORadj 45.3 0.22, 9521 0.61 ORadj 1.11 0.92, 1.34 0.57
Femoral neck osteopenia (T-
score\-1)
ORadj 21.3 1.96, 231 0.25 ORadj 1.17 1.05, 1.30 0.26
Femoral neck osteoporosis (T-
score B-2.5)
ORadj 1.41 0.08, 26.4 0.55 ORadj 1.01 0.89, 1.13 0.55
History of previous fracture ORadj 10.5 2.07, 53.3 0.10 ORadj 1.09 1.01, 1.17 0.08
Statistically significant models are in bold. Complete data for all covariates were available for 116 in the femoral neck and total hip models.
Complete data for all covariates of the fracture model were available for 128
BMD bone mineral density, OPG-Ab anti-OPG antibody
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increase the risk of breaking tolerance and promote
autoantibody production. Longitudinal studies are required
to explore the timing or triggering factor of OPG-Ab
development during the course of disease. Height was
lower in patients positive for OPG-Ab compared with those
who were negative. This may have been explained by their
older age, but another possibility would be the increased
prevalence of vertebral fractures in this group. No associ-
ations were demonstrated between OPG-Ab and disease
activity or inflammatory markers which suggest that OPG-
Ab may be independent of local inflammation in axSpA.
This small cohort had variable exposures to non-bio-
logical DMARDs and NSAIDs. While no association with
these drug exposures was observed, the study was not
adequately powered to explore such associations with
OPG-Ab development. The association between TNFi use
and OPG-Ab requires further exploration. Patients com-
menced on TNFi would have higher disease activity and
inflammatory burden, which may promote autoantibody
formation. Low BMD and fracture history were more
prevalent in OPG-Ab-positive patients, which would
explain increased bisphosphonate use in this group. A
similar trend for increased TNFi and bisphosphonate use
was seen in OPG-Ab-positive RA patients [13].
There were several limitations in this study. The associ-
ation with fractures, although statistically significant, was
based on a small number of events which are reflected by the
wide confidence intervals. The intervals between measure-
ment of OPG-Ab and BMD were variable. Although the
median time between recruitment and DXA scan was
0.2 months, we included BMD results from up to four years
before and one year after recruitment. We do not think that
this would have substantially altered results since BMD is
likely to have been relatively stable in this cohort of patients
with well-established axSpA. In this regard, it has previously
been found that accelerated bone loss predominantly occurs
in early disease [7] and so it is likely that, in this population
where median disease duration was 6.4 years, BMD results
would have been stable. Another limitation is that the find-
ings were primarily based on male axSpA patients who are
more commonly affected by accelerated bone loss and ver-
tebral fractures [8]. Due to the small number of female
patients, it was not possible to evaluate the impact of gender
on OPG-Ab positivity. Given most patients had established
disease, it is important to emphasise that the results cannot be
extrapolated to newly diagnosed younger patients who are at
relatively higher risk of osteoporotic fractures [7]. A
potential limitation was that not all self-reported fractures
could be validated but this is unlikely to have resulted in
systematic bias since fracture assessments were completed
before the measurements for OPG-Ab were performed. It is
of interest that the proportion of vertebral fractures in this
cohort was lower than that reported in some historical
cohorts [2]. This may reflect improved management or may
have been due to the fact that lateral spine imaging was only
performed in patients with symptoms suggestive of a clinical
vertebral fracture. Because of that it is entirely possible that
morphometric fractures may have not been detected.
In conclusion, the results of this study raise the possibility
that OPG-Ab may play a role in axSpA-associated systemic
bone loss in some patients and that these antibodies may be a
biomarker for risk of bone loss and fractures. However, a
causative role cannot be confirmed by this cross-sectional
study. Larger longitudinal studies are needed to establish and
quantify the impact of OPG-Ab, their functionality, and to
explore the potential of early detection and prevention of
OPG-Ab associated osteoporosis.
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